Life Technologies’s Acquisition by Thermo Fisher Scientific

On April 15, 2013, Thermo Fisher Scientific Inc., the world leader in serving science, and Life Technologies Corporation, a leading life sciences company, signed a definitive agreement under which Thermo Fisher will acquire Life Technologies for $76.00 in cash per fully diluted common share, or approximately $13.6 billion, plus the assumption of net debt at close ($2.2 billion as of year end 2012). Cravath represented Life Technologies in connection with this transaction, which is expected to close early in 2014, subject to a Life shareholder vote and satisfying customary closing conditions, including regulatory approvals.

The Cravath team included partners Richard Hall and Minh Van Ngo and associates Stephanie R. Gallina and Patricia M. Groot on corporate matters; partner Michael L. Schler and associate Jonathan D. Grossman on tax matters; partner Eric W. Hilfers, practice area attorney Michael Krasnovsky and associate Matthew Cantor on executive compensation and benefits matters; partner Matthew Morreale on environmental matters; partner David J. Kappos and associate Gregory R. Baden on intellectual property matters; and partner Christine A. Varney and associate Margaret T. Segall on antitrust matters. Raku Raku and Rachael G. Coffey also worked on corporate matters and Sharonmoyee Goswami also worked on antitrust matters.